Healthcare >> Analyst Interviews >> January 10, 2001
TWST: What has been the attraction for these specialty pharma stocks, COREY DAVIS joined Hambrecht & Quist in 1997 covering the emerging
pharmaceutical industry with an emphasis on mid-cap emerging pharma
names like Alza, Forest, Shire, King, and Medicis. Mr. Davis also
focuses on drug delivery and specialty firms like Emisphere and Neose.
He also co-covers with Alex Zisson the big-cap pharmaceuticals such as
Lilly, Schering-Plough, Merck, Pfizer, and Glaxo. Prior to joining H&Q,
Mr. Davis received a PhD in Molecular Biology from Princeton University.
He graduated Magna Cum Laude in 1991 with High Honors in Biology from
Middlebury College, where he was elected to Phi Beta Kappa. Profile
and will that attraction continue?
Dr. Davis: It's all about growth, and over the past few years many of